HYPMY Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -12.95% compared to Hypera SA's net margin of --. Hypera SA's return on equity of 7.07% beat CEL-SCI's return on equity of --.

Hypera SA has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 6699.55%. Given that CEL-SCI has higher upside potential than Hypera SA, analysts believe CEL-SCI is more attractive than Hypera SA.

Hypera SA has a beta of 0.812, which suggesting that the stock is 18.793% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.097%.

Hypera SA has a quarterly dividend of $0.05 per share corresponding to a yield of 4.08%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hypera SA pays 58.71% of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend. Hypera SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hypera SA quarterly revenues are $184.4M, which are larger than CEL-SCI quarterly revenues of --. Hypera SA's net income of -$23.9M is lower than CEL-SCI's net income of -$6.6M. Notably, Hypera SA's price-to-earnings ratio is 21.06x while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hypera SA is 2.64x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -12.95% compared to Hypera SA's net margin of -711.67%. Hypera SA's return on equity of 7.07% beat IGC Pharma's return on equity of -116.24%.

Hypera SA has a consensus price target of --, signalling downside risk potential of --. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1059.83%. Given that IGC Pharma has higher upside potential than Hypera SA, analysts believe IGC Pharma is more attractive than Hypera SA.

Hypera SA has a beta of 0.812, which suggesting that the stock is 18.793% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.452, suggesting its more volatile than the S&P 500 by 45.212%.

Hypera SA has a quarterly dividend of $0.05 per share corresponding to a yield of 4.08%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hypera SA pays 58.71% of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend. Hypera SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hypera SA quarterly revenues are $184.4M, which are larger than IGC Pharma quarterly revenues of $257K. Hypera SA's net income of -$23.9M is lower than IGC Pharma's net income of -$1.8M. Notably, Hypera SA's price-to-earnings ratio is 21.06x while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hypera SA is 2.64x versus 20.11x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -12.95% compared to Hypera SA's net margin of -49.65%. Hypera SA's return on equity of 7.07% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Hypera SA has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that NovaBay Pharmaceuticals has higher upside potential than Hypera SA, analysts believe NovaBay Pharmaceuticals is more attractive than Hypera SA.

Hypera SA has a beta of 0.812, which suggesting that the stock is 18.793% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Hypera SA has a quarterly dividend of $0.05 per share corresponding to a yield of 4.08%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hypera SA pays 58.71% of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend. Hypera SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hypera SA quarterly revenues are $184.4M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Hypera SA's net income of -$23.9M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Hypera SA's price-to-earnings ratio is 21.06x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hypera SA is 2.64x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Raia Drogasil SA has a net margin of -12.95% compared to Hypera SA's net margin of 1.63%. Hypera SA's return on equity of 7.07% beat Raia Drogasil SA's return on equity of 18.54%.

Hypera SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Raia Drogasil SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Hypera SA has higher upside potential than Raia Drogasil SA, analysts believe Hypera SA is more attractive than Raia Drogasil SA.

Hypera SA has a beta of 0.812, which suggesting that the stock is 18.793% less volatile than S&P 500. In comparison Raia Drogasil SA has a beta of 0.163, suggesting its less volatile than the S&P 500 by 83.749%.

Hypera SA has a quarterly dividend of $0.05 per share corresponding to a yield of 4.08%. Raia Drogasil SA offers a yield of 2.5% to investors and pays a quarterly dividend of $0.01 per share. Hypera SA pays 58.71% of its earnings as a dividend. Raia Drogasil SA pays out -- of its earnings as a dividend. Hypera SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hypera SA quarterly revenues are $184.4M, which are smaller than Raia Drogasil SA quarterly revenues of $1.7B. Hypera SA's net income of -$23.9M is lower than Raia Drogasil SA's net income of $28M. Notably, Hypera SA's price-to-earnings ratio is 21.06x while Raia Drogasil SA's PE ratio is 21.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hypera SA is 2.64x versus 0.57x for Raia Drogasil SA. Usually stocks with elevated PS ratios are considered overvalued.